Last reviewed · How we verify
Moxifloxacin 0.5% ophthalmic solution
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and causing bacterial cell death. Used for Bacterial conjunctivitis, Bacterial keratitis, Bacterial corneal ulcer.
At a glance
| Generic name | Moxifloxacin 0.5% ophthalmic solution |
|---|---|
| Also known as | Vigamox |
| Sponsor | Johns Hopkins University |
| Drug class | Fluoroquinolone antibiotic |
| Target | Bacterial DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
As a broad-spectrum fluoroquinolone, moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and transcription. This dual mechanism results in rapid bactericidal activity against a wide range of gram-positive and gram-negative ocular pathogens. The ophthalmic formulation delivers high local concentrations to the eye while minimizing systemic exposure.
Approved indications
- Bacterial conjunctivitis
- Bacterial corneal ulcers
- Post-operative ocular infections
Common side effects
- Ocular irritation or discomfort
- Conjunctival hyperemia
- Taste perversion (from nasolacrimal drainage)
- Photophobia
Key clinical trials
- Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis (NA)
- Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction (PHASE3)
- PRO-232 in Patients Subjected to Cataract Surgery (PHASE3)
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo. (PHASE1)
- Dropless Pars Plana Vitrectomy Study (PHASE4)
- Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects (PHASE1)
- Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery (PHASE4)
- The Effect of Gland Expression on the Regeneration of Meibomian Gland (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin 0.5% ophthalmic solution CI brief — competitive landscape report
- Moxifloxacin 0.5% ophthalmic solution updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI